

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final draft guidance

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| No issues identified at scoping.  |

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No other issues identified.  |

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No other issues identified.  |

- |  |
|--|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? |
|--|

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer

<p>If so, what are the barriers to, or difficulties with, access for the specific group?</p>	<p>The panel noted that its recommendation is optimised to people with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, that is, people with lower functional disability. This is because a) the trial for durvalumab only contained people with ECOG performance status of 0 or 1, and b) the cost-comparison methodology requires like-for-like comparison with an established comparator (in this case, atezolizumab), which is also optimised to ECOG performance status of 0 or 1.</p>
<p>5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?</p>	<p>Assessment of ECOG performance status can be affected by physical, sensory or learning disabilities, and communication difficulties.</p>
<p>6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?</p>	<p>Advice is given in recommendation paragraph 1.2 on accounting for physical, sensory or learning disabilities, and communication difficulties when assessing ECOG performance status.</p>
<p>7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?</p>	<p>No. Advice on accounting for physical, sensory or learning disabilities, and communication difficulties when using ECOG performance status is included in paragraph 1.2.</p>

**Approved by Associate Director (name):** Ian Watson

**Date:** 13 January 2025